Quantcast

Latest Clinical trial Stories

2014-10-15 23:06:56

Clinical Conductor CTMS is now fitted with new and enhanced functionality set to optimize the way organizations conduct complex oncology clinical research. Rochester, NY (PRWEB) October 15, 2014 The team behind Clinical Conductor is proud to announce brand new enhancements to the industry-leading CTMS. This first oncology focused release of several in the coming quarters adds a multitude of advanced features and functionalities designed to optimize the management and execution of oncology...

2014-10-15 08:29:30

BUFFALO, N.Y., Oct. 15, 2014 /PRNewswire/ -- Hanmi Pharmaceuticals and Collaborative Partner Kinex Pharmaceuticals announce today preliminary results from a Phase I Clinical Study of Oratecan - an oral form of the approved intravenously administered cancer drug irinotecan, with HM30181, a potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. Irinotecan is a type 1 DNA topoisomerase inhibitor, marketed under the trade name Camptosar. It is approved for the...

2014-10-14 08:34:17

First Patient Has Begun Treatment Process; Additional Patients Being Assessed; Waiting List Established BETHESDA, Md., Oct. 14, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the DCVax-L Hospital Exemption Program that was approved by the German regulatory authority earlier this year is now under way. The first patient with Glioblastoma...

2014-10-14 04:22:26

KALAMAZOO, MI and KATOWICE, Poland, Oct. 14, 2014 /PRNewswire/ -- Ablative Solutions, Inc. (ASI), a privately held company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has treated the first patient in the Peregrine Study. Patients enrolled in the study receive targeted therapy using the investigational Peregrine System(TM) Infusion Catheter to treat sympathetic nerves located in the outer region of arteries. The interruption of these nerve...

2014-10-13 12:26:55

MONT-SAINT-GUIBERT, Belgium, October 13, 2014 /PRNewswire/ -- - CHART-1 trial represents the world's first Phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart failure - To date, 12 countries have granted authorization for Cardio3 BioSciences' Phase III (CHART-1) - The progress of CHART-1 is in line with objectives Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a...

2014-10-13 12:26:17

DUBLIN, Oct. 13, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) - Research Report, 2013 - 2020" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Nonalcoholic Steatohepatitis (NASH) also known as silent disease is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are...

2014-10-12 23:01:50

MarketOptimizer.org adds “Ventricular Septal Defect Global Clinical Trials Review, H2, 2014” to its store. This report provides elemental information and data relating to the clinical trials on Ventricular Septal Defect. Dallas, Texas (PRWEB) October 12, 2014 A ventricular septal defect (VSD) is a defect in the ventricular septum, the wall dividing the left and right ventricles of the heart. The ventricular septum consists of an inferior muscular and superior membranous portion and is...

2014-10-12 23:00:34

MarketOptimizer.org adds “Unstable Angina Global Clinical Trials Review, H2, 2014” to its store. This report provides elemental information and data relating to the clinical trials on Unstable Angina. Dallas, TX (PRWEB) October 13, 2014 Unstable angina is angina pectoris caused by disruption of an atherosclerotic plaque with partial thrombosis and possibly embolization or vasospasm. It is characterized by at least one of the following: Occurs at rest or minimal exertion and usually...

2014-10-11 23:02:29

MarketOptimizer.org adds “Vascular Calcification Global Clinical Trials Review, H2, 2014” to its store. This report provides elemental information and data relating to the clinical trials on Vascular Calcification. Dallas, Texas (PRWEB) October 11, 2014 Clinical trial report, “Vascular Calcification Global Clinical Trials Review, H2, 2014″ provides data on the Vascular Calcification clinical trial scenario. This report provides elemental information and data relating to the...

2014-10-10 12:24:47

WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 10, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ(®) (lorcaserin HCl) was published in the October issue of Postgraduate Medicine, a peer-reviewed medical journal for physicians. In the pooled analysis, BELVIQ 10 mg twice daily, as compared to placebo and both in conjunction with diet and exercise, was associated...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.